Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Colonic Neoplasms × nilotinib × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Gastrointestinal Stromal Tumors 1 Gastrointestinal Neoplasms 1 Colonic Neoplasms 1

Interventions

Fluorouracil 10 Leucovorin 9 Oxaliplatin 8 Bevacizumab 6 Irinotecan 5 Capecitabine 3 aflibercept 2 Exercise 2 Cetuximab 2 Atorvastatin 2 tucatinib 1 trifluridine tipiracil drug combination 1 trastuzumab biosimilar HLX02 1 sulindac sulfone 1 sargramostim 1 retrovector encoding mutant anti-cyclin G1 1 regorafenib 1 poly ICLC 1 pidilizumab 1 pembrolizumab 1 p53 peptide 264-272, human 1 nilotinib 1 lonafarnib 1 irofulven 1 infigratinib 1 grp protein, Drosophila 1 gevokizumab 1 galactomannan 1 delta-8-tetrahydrocannabinol 1 dehydroftorafur 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02774512 2017-10-06

ZAK-0

Institut Bergonié

Phase EARLY_PHASE1 Withdrawn

Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡